MATSUMOTO Kunio

Last updated: Dec 3, 2019 at 16:41

Name	MATSUMOTO Kunio
Affiliation	Kanazawa University
Section	Cancer Research Institute, Cancer Research Institute
Degree	Ph.D.(Osaka University)

Research Interests

Macrocyclic peptide(1) , Artificial HGF(1) , Tumor microenvironment(34) , Growth Factor(23) , Metastasis(70) , HGF(12)

Research Areas

Oncology / Tumor biology /
Biological Science / Functional biochemistry /

Academic & Professional Experience

Plain Text

1986

1990

: Assistant Professor Assistant Professor　

1990

1993

: Assistant Professor Assistant Professor　

1993

1994

: Assistant Professor Assistant Professor　

1994

1996

: Assistant Professor Assistant Professor　

1996

2001

: Associate Professor Associate Professor　

1998

1999

: Visiting Associate Professor Visiting Associate Professor　

2001

2007

: Associate Professor Associate Professor　

2007

-: Professor　

Education

Plain Text

1986

Biochemistry, Graduate School, Division of Natural Science, Osaka University

1981

Biology, Faculty of Science, Kanazawa University

Awards & Honors

Plain Text

2014

The Commendation for Science and Technology by MEXT, Prizes for Science and Technology

2006

Nature Medicine-AnGes MG BioMedical Award (Main Award)

2002

The 3rd Biobusiness Competition Japan Special Award by an Examining Comittee

2001

The Most Valuable Article Award for 30 Anniversary Memorial of Nikkei Science Journal

1999

Kudo Foundation Award

1997

Incitement Award of the Japanese Cancer Association

1996

JB Award from the Japanese Biochemical Society

1991

Academic Incitement Award of Japanese Industrial Hygiene Dermatology Association

Published Papers

Plain Text

Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.

Miao W, Sakai K, Sato H, Imamura R, Jangphattananont N, Takagi J, Nishita M, Minami Y, Matsumoto K

Cancer science 110(10) 3340-3349 Oct 2019 [Refereed]

Distinct Localization of Mature HGF from its Precursor Form in Developing and Repairing the Stomach.

Jangphattananont N, Sato H, Imamura R, Sakai K, Terakado Y, Murakami K, Barker N, Oshima H, Oshima M, Takagi J, Kato Y, Yano S, Matsumoto K

International journal of molecular sciences 20(12) Jun 2019 [Refereed]

Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor

Sakai K, Passioura T, Sato H, Ito K, Furuhashi H, Umitsu M, Takagi J, Kato Y, Mukai H, Warashina S, Zouda M, Watanabe Y, Yano S, Shibata M, Suga H*, Matsumoto K*.

Nature Chemical Biology 00(00) 00-00 May 2019 [Refereed]

Cellular signaling and gene expression profiles evoked by a bivalent macrocyclic peptide that serves as an artificial MET receptor agonist.

Miao W, Sakai K, Ozawa N, Nishiuchi T, Suzuki Y, Ito K, Morioka T, Umitsu M, Takagi J, Suga H, Matsumoto K

Scientific reports 8(1) 16492 Nov 2018 [Refereed]

MET Activation by a Macrocyclic Peptide Agonist that Couples to Biological Responses Differently from HGF in a Context-Dependent Manner.

Miao W, Sakai K, Imamura R, Ito K, Suga H, Sakuma T, Yamamoto T, Matsumoto K

International journal of molecular sciences 19(10) Oct 2018 [Refereed]

Hepatocyte growth factor in physiology and infectious diseases.

Imamura R, Matsumoto K

Cytokine 98 97-106 Oct 2017 [Refereed]

Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer.

Jahangiri A, Nguyen A, Chandra A, Sidorov MK, Yagnik G, Rick J, Han SW, Chen W, Flanigan PM, Schneidman-Duhovny D, Mascharak S, De Lay M, Imber B, Park CC, Matsumoto K, Lu K, Bergers G, Sali A, Weiss WA, Aghi MK

Proceedings of the National Academy of Sciences of the United States of America 114(41) E8685-E8694 Oct 2017 [Refereed]

Targeting the hepatocyte growth factor/Met pathway in cancer.

De Silva DM, Roy A, Kato T, Cecchi F, Lee YH, Matsumoto K, Bottaro DP

Biochemical Society transactions 45(4) 855-870 Aug 2017 [Refereed]

Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.

Tode N, Kikuchi T, Sakakibara T, Hirano T, Inoue A, Ohkouchi S, Tamada T, Okazaki T, Koarai A, Sugiura H, Niihori T, Aoki Y, Nakayama K, Matsumoto K, Matsubara Y, Yamamoto M, Watanabe A, Nukiwa T, Ichinose M

Cancer science 108(6) 1263-1270 Jun 2017 [Refereed]

Hepatocyte growth factor/MET in cancer progression and biomarker discovery.

Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP

Cancer science 108(3) 296-307 Mar 2017 [Refereed]

Different growth and metastatic phenotypes associated with a cell-intrinsic change of Met in metastatic melanoma.

Adachi E, Sakai K, Nishiuchi T, Imamura R, Sato H, Matsumoto K

Oncotarget 7(43) 70779-70793 Oct 2016 [Refereed]

Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies.

Umitsu M, Sakai K, Ogasawara S, Kaneko MK, Asaki R, Tamura-Kawakami K, Kato Y, Matsumoto K, Takagi J

Scientific reports 6 33149 Sep 2016 [Refereed]

Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.

Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K

Cancer research 76(6) 1506-1516 Mar 2016 [Refereed]

Hepatocyte growth factor and Met in drug discovery.

Sakai K, Aoki S, Matsumoto K

Journal of biochemistry 157(5) 271-284 May 2015 [Refereed]

Artificial human Met agonists based on macrocycle scaffolds.

Ito K, Sakai K, Suzuki Y, Ozawa N, Hatta T, Natsume T, Matsumoto K, Suga H

Nature communications 6 6373 Mar 2015 [Refereed]

A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene.

Tada Y, Hiroshima K, Shimada H, Morishita N, Shirakawa T, Matsumoto K, Shingyoji M, Sekine I, Tatsumi K, Tagawa M

SpringerPlus 4 358 2015 [Refereed]

HGF-Met Pathway in Regeneration and Drug Discovery.

Matsumoto K, Funakoshi H, Takahashi H, Sakai K

Biomedicines 2(4) 275-300 Oct 2014 [Refereed]

Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor.

Oyanagi J, Kojima N, Sato H, Higashi S, Kikuchi K, Sakai K, Matsumoto K, Miyazaki K

Experimental cell research 326(2) 267-279 Aug 2014 [Refereed]

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.

Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S

Oncotarget 5(13) 4920-4928 Jul 2014 [Refereed]

Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.

Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Matsumoto K, Yonekura K, Yano S

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 9(6) 775-783 Jun 2014 [Refereed]

Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury.

Adachi E, Hirose-Sugiura T, Kato Y, Ikebuchi F, Yamashita A, Abe T, Fukuta K, Adachi K, Matsumoto K

Pharmacology 94(3-4) 190-197 2014 [Refereed]

Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.

Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T, Matsumoto K, Yonekura K, Yoshie O, Yano S

Cancer science 104(12) 1640-1646 Dec 2013 [Refereed]

Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model.

Hayakawa H, Ichihara E, Ohashi K, Ninomiya T, Yasugi M, Takata S, Sakai K, Matsumoto K, Takigawa N, Tanimoto M, Kiura K

Cancer science 104(11) 1440-1446 Nov 2013 [Refereed]

Interruption of the HGF paracrine loop by NK4, an HGF antagonist, reduces VEGF expression of CT26 cells.

Kubota T, Matsumura A, Taiyoh H, Izumiya Y, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S, Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Nakamura T, Matsumoto K, Nakamura T, Otsuji E

Oncology reports 30(2) 567-572 Aug 2013 [Refereed]

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.

Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S

International journal of cancer 133(2) 505-513 Jul 2013 [Refereed]

α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.

Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, Matsugo S, Matsumoto K

Cancer letters 335(2) 472-478 Jul 2013 [Refereed]

Molecular targeting of hepatocyte growth factor by an antagonist, NK4, in the treatment of rheumatoid arthritis.

Tsunemi S, Iwasaki T, Kitano S, Matsumoto K, Takagi-Kimura M, Kubo S, Tamaoki T, Sano H

Arthritis research & therapy 15(4) R75 Jul 2013 [Refereed]

Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes.

Nakayama M, Sakai K, Yamashita A, Nakamura T, Suzuki Y, Matsumoto K

Cytokine 62(3) 446-452 Jun 2013 [Refereed]

Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans.

Sugiura T, Takahashi S, Sano K, Abe T, Fukuta K, Adachi K, Nakamura T, Matsumoto K, Nakamichi N, Kato Y

Journal of pharmaceutical sciences 102(1) 237-249 Jan 2013 [Refereed]

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S

PloS one 8(5) e62104 2013 [Refereed]

Suppression of fibrogenic gene expression and liver fibrosis using a synthetic prostacyclin agonist.

Xu Q, Sakai K, Suzuki Y, Tambo C, Sakai Y, Matsumoto K

Biomedical research (Tokyo, Japan) 34(5) 241-250 2013 [Refereed]

Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.

Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, Yasumoto K, Matsumoto K, Yano S

PloS one 8(12) e84700 2013 [Refereed]

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S

Molecular cancer therapeutics 11(10) 2149-2157 Oct 2012 [Refereed]

Repair of segmental bone defects in rabbit tibia promoted by a complex of β-tricalcium phosphate and hepatocyte growth factor.

Goshima K, Nakase J, Xu Q, Matsumoto K, Tsuchiya H

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 17(5) 639-648 Sep 2012 [Refereed]

Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.

Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S

The American journal of pathology 181(3) 1034-1043 Sep 2012 [Refereed]

Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.

Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S

Clinical cancer research : an official journal of the American Association for Cancer Research 18(13) 3592-3602 Jul 2012 [Refereed]

Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.

Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S

Clinical cancer research : an official journal of the American Association for Cancer Research 18(6) 1663-1671 Mar 2012 [Refereed]

Suppression of acute hepatic injury by a synthetic prostacyclin agonist through hepatocyte growth factor expression.

Xu Q, Nakayama M, Suzuki Y, Sakai K, Nakamura T, Sakai Y, Matsumoto K

American journal of physiology. Gastrointestinal and liver physiology 302(4) G420-9 Feb 2012 [Refereed]

Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.

Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yasumoto K, Yano S

The American journal of pathology 179(3) 1483-1493 Sep 2011 [Refereed]

3-D collagen-dependent cell surface expression of MT1-MMP and MMP-2 activation regardless of integrin β1 function and matrix stiffness.

Sakai K, Nakamura T, Suzuki Y, Imizu T, Matsumoto K

Biochemical and biophysical research communications 412(1) 98-103 Aug 2011 [Refereed]

Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.

Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H, Nakamura T, Matsumoto K

International journal of cancer 127(8) 1948-1957 Oct 2010 [Refereed]

hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells.

Onimaru M, Ohuchida K, Mizumoto K, Nagai E, Cui L, Toma H, Takayama K, Matsumoto K, Hashizume M, Tanaka M

Cancer science 101(3) 735-742 Mar 2010 [Refereed]

Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.

Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S

Clinical cancer research : an official journal of the American Association for Cancer Research 16(1) 174-183 Jan 2010 [Refereed]

Facilitated tendon-bone healing by local delivery of recombinant hepatocyte growth factor in rabbits.

Nakase J, Kitaoka K, Matsumoto K, Tomita K

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association 26(1) 84-90 Jan 2010 [Refereed]

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S

Clinical cancer research : an official journal of the American Association for Cancer Research 15(21) 6630-6638 Nov 2009 [Refereed]

Up-regulation of integrin beta3 in radioresistant pancreatic cancer impairs adenovirus-mediated gene therapy.

Egami T, Ohuchida K, Yasui T, Mizumoto K, Onimaru M, Toma H, Sato N, Matsumoto K, Tanaka M

Cancer science 100(10) 1902-1907 Oct 2009 [Refereed]

Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin.

Tamase A, Muraguchi T, Naka K, Tanaka S, Kinoshita M, Hoshii T, Ohmura M, Shugo H, Ooshio T, Nakada M, Sawamoto K, Onodera M, Matsumoto K, Oshima M, Asano M, Saya H, Okano H, Suda T, Hamada J, Hirao A

Proceedings of the National Academy of Sciences of the United States of America 106(40) 17163-17168 Oct 2009 [Refereed]

Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association.

Sakai K, Nakamura T, Matsumoto K, Nakamura T

The Journal of biological chemistry 284(33) 22491-22499 Aug 2009 [Refereed]

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S

Cancer research 68(22) 9479-9487 Nov 2008 [Refereed]

Liver organogenesis promoted by endothelial cells prior to vascular function.

Matsumoto K, Yoshitomi H, Rossant J, Zaret K.

Science 294 559-563 2001 [Refereed]

Conference Activities & Talks

Plain Text

Ror1 promotes invasion of lung adenocarcinoma cells through small GTPase Rif -mediated filopodia formation.

Nishita M, Nishikaku I, Yoshida E, Kamizaki K, Shibuya H, Matsumoto K, Minami Y.

ASCB-EMBO 2018 meeting. 9 Dec 2018

Macrocyclic peptides targeting HGF-MET.

MATSUMOTO Kunio

4th International Conference on Circular Propteins and Peptides. 30 Nov 2018

Macrocyclic peptide technology targeting HGF and METreceptor.

MATSUMOTO Kunio

The 2nd NanoLSI International Symposium. 19 Nov 2018

Rif small GTPase mediates Ror1 signaling to induce filopodia formation and invasion of lung adenocarcinoma cells.

Nishita M, Nishikaku I, Yoshida E, Shibuya H, Matsumoto K, Minami Y.

5 Jun 2018

Novel Biological Function of HGF receptor Met in Immune Response.

Imamura R, Sato H, Sakai K, Matsumoto K.

The 1st NanoLSI International Symposium. 21 Feb 2018

Growth factor signaling: dynamics, cancer, and drug discovery.

Matsumoto K.

The 1st NanoLSI International Symposium. 21 Feb 2018

HS-AFM revealed unexpected mechanism of MET receptor activation.

Sakai K, Furuhashi H, Shibata M, Matsumoto K.

The 1st NanoLSI International Symposium. 21 Feb 2018

Association Memberships

THE JAPANESE SOCIETY FOR REGENERATIVE MEDICINE(435) , THE JAPANESE BIOCHEMICAL SOCIETY(1765) , THE JAPANESE CANCER ASSOCIATION(1400)

Works

Plain Text

Therapeutic approach with HGF and NK4

2007

Role of HGF in pharmaceutical actions of PGs in tissue regeneration

2008

Social Contribution

Plain Text

Foundation of Bio-Venture

[Organizing Member, Others] Dec 2001 - Today